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PUBLIC HEALTH LESSONS FROM A 
PILOT PROGRAMME TO REDUCE 
MOTHER-TO-CHILD 
TRANSMISSION OF HIV-1 IN 
KHAYELITSHA 
M F Abdullah, T Young, L Bitalo, N Coetzee, J E Myers 
Objective. Short-course antiretroviral therapy (ART) has been 
shown to be effective in reducing mother-to-child 
transmission (MTCT) ofHIV-1. This article details the public 
health lessons learnt from a district-based pilot programme 
where a short-murse zidovudine (ZDV) regimen has been 
used in a typical South African peri-urban setting. 
Methods. The pilot programme was initiated at two midwife 
obstetric units in January 1999. Lay counsellors conducted 
pre- and post-test counselling and nurses took blood for HIV 
enzyme-linked imrnunosorbent assay (EUSA) testing. Short-
course ZDV was administered antenatally (from 36 weeks' 
gestation) and during labour. Mother-infant pairs were 
followed up at eight child health clinics where free formula 
feed was dispensed weekly. Infants received co-trimoxazole 
prophylaxis and were EUSA tested for HIV at 9 and 18 
months. After 17 months protocol changes aimed at 
eliminating weaknesses included initiation of ZDV at 34 
weeks, self-administration of the first dose of ZDV with the 
onset of labour, and rapid HIV testing for both mothers and 
infants. 
Results. Voluntary counselling and testing was shown to be 
highly acceptable, with individual counselling more effective 
than group counselling. Based on less than optimal 
availability of records, ZDV utilisation was encouraging with 
up to 59% of subjects initiating treatment, 3 weeks' median 
duration of ZDV use, and up to 88% receiving at least one 
intrapartum ZDV dose. Self-administration of the 
intrapartum dose reached 41%. 
Conclusions . Short-course antenatal and intrapartum ART to 
prevent MTCT of HIV1 was shown to be feasible. 
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The Joint United Nations Programme on HIV I AIDS estimates 
that there were 620 000 new paediatric HIV infections 
worldwide in 1999,' almost all due to mother-to-child 
transmission (MTCT). In the developed world, significant 
reduction in MTCT has been achieved by the widespread use 
of relatively long courses of zidovudine (ZDV) in pregnancy 
(ACT G076),u widespread use of highly active antiretroviral 
therapy (HAART) and elective caesarean section. In developing 
countries, trials of short-course antiretroviral therapy (ART) 
have demonstrated reductions in transmission of one-half to 
one-third:l-7 
In January 1999, the Western Cape Provincial Health 
Department implemented a pilot programme to prevent MTCT 
in the Khayelitsha health district. Since efficacy of the treatment 
intervention was not at issue, the purpose of limiting the 
programme to one health district was to gain a greater 
understanding of operational aspects of implementation as 
well as the acceptability of the intervention. 
M ETHO DS 
Khayelitsha is a sprawling peri-urban settlement with a mix of 
formal and informal dwellings. It lies some 30 km from the 
Cape Town city centre and has an estimated population of 
325 000. The background HIV prevalence (for the district) was 
estimated at 16% and 22% for the years 1998 and 1999, 
respectively.• There is no hospital, and the programme was 
implemented at the two midwife obstetric units (MOUs) in the 
district. The MOUs are staffed by midwives providing primary 
level maternity care, with referral of complicated cases. MOU1 
has approximately double the patient load of MOU2. At 
booking, women attending the two MOU antenatal clinics were 
offered voluntary counselling and testing (VCT). The 
counselling content included an overview of HN transmission 
risk, feeding practices, and the role of ART. Trained HlV 
counsellors did counselling and HJV enzyme-linked 
immunosorbent assay (ELISA) testing was done at a distant 
teaching hospital laboratory. Women received results of the test 
at the next vi it. 
Women at MOU1 made a choice to test after group 
counselling. Only those electing to test receivt>d individual 
counselling. At MOU2, women were allowed to make a choice 
after individual counselling. The employment and 
management of the counsellors was contracted out to Lifeline, 
an GO specialising in this field . 
Those accepting VCT and who subsequently tested HN-
positive were entered into the programme. At 36 weeks' 
gestation oral ZDV (300 mg twice daily) was commenced and 
dispensed weekly until the woman presented in labour, when 
ZDV (300 mg 3-hourly) was administered until delivery. On 
discharge, mothers were again counselled about the risk of 
transmission during breast-feeding. Formula feeds were 
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dispensed to those who chose not to breast-feed. Mother-to-
child pairs were followed up at any one of eight child health 
clinics in the district where a weekly supply of formula (up to 6 
months of age in the first period and up to 9 months in the 
second period) and co-trimoxazole prophylaxis (6 weeks to 18 
months of age) were dispensed. Infants were ELISA tested for 
HIV at 9 and 18 months. 
In June 2000, 17 months after commencement, changes to the 
programme were instituted to enhance the programme 
intervention. From ongoing surveillance it became apparent 
that booking gestational age was being underestimated. 
Commencement of ZDV was changed from 36 to 34 weeks' 
gestation and women were advised to self-administer the first 
dose of ZDV with the onset of labour. Protocol changes were 
also made in respect of testing. Because of long laboratory 
result turnaround times, on-site rapid HIV testing replaced the 
centralised laboratory-based ELISA tests. The change to rapid 
testing improved the follow-up and testing of infants as nurses 
at the child health clinics expressed a preference for performing 
heel-prick rapid tests over venepuncture in infants. 
In the run-up to the protocol changes a novel management 
approach was employed combining central and local 
management expertise in a way that allowed each component 
of management to focus on its functions. The provincial level 
tasks concentrated on vertical support, freeing up financial 
resources, procuring drugs and supplies and ensuring 
necessary personnel and training. Local management focused 
on practical organisation of the service, staff motivation, 
consultation with community structures and organisations and 
patient follow-up. Co-ordination of the programme also 
required the involvement of managers from secondary and 
tertiary referral hospitals serving the district, as upwards of 
20% of women entered into the programme were referred to 
these facilities for delivery. 
A monitoring system to track the enrollment, testing, 
treatment and follow-up of all women presenting at the two 
MOUs was developed and implemented. The system relied on 
primary data collection by nurses using modified service 
logbooks and data forms. Data presented here are taken from 
the monitoring database, and we report point estimates (means 
or medians and proportions) from the programme audit over 
two successive periods, before Oanuary 1999- May 2000), and 
after Oune 2000 -December 2000) the protocol changes 
described above were made. 
il RESULTS 
Voluntary counselling and testing 
Table I describes findings in respect of VCT. Mean gestational 
age at booking for women who accepted VCT was 26 weeks. In 
the first period Oanuary 1999- May 2000) there were 9 997 new 
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bookings, of whom 7 229 (72%) accepted testing for HIV. Of the 
women tested, 1 185 (16%) were found to be HIV-infected and 
were enrolled into the prograrrune. In the second period Oune-
December 2000) there were 4 142 new bookings; 2 790 women 
(67%) accepted HIV testing and 567 (20.3%) were HIV-infected. 
HIV test acceptance was consistently higher at MOU2 (93% 
in both periods), and dropped in MOUI from 61% in the first 
period to 50% in the second period. Test result tum-around 
time was 11 days in the first period. This was reduced to < 1 
day in the second period following the change to rapid testing. 
High rates of post-test counselling were achieved at both 
sites and in both time periods, 94% and 89% of HIV-positive 
women receiving post-test counselling in the first and second 
periods, respectively. The percentage of HIV-negative women 
who received post-test counselling increased from 87% to 98% 
over the two time periods. Altogether, over both time periods, 
8 267 HIV-negative women received post-test counselling, 
representing 82.5% of all women accepting testing. 
ZDV administration 
In order to assess ZDV administration (as a proxy for 
compliance) all available records for women who were entered 
into the programme were reviewed at the end of both periods 
(Table II). These records represented 60% and 44% of 
participants in the first and second periods, respectively. 
Unavailable records were the result of referral to other facilities 
or poor record keeping. 
Of 710 women whose records were reviewed from the first 
period, 463 (65%) received at least one week's supply of ZDV, 
361 (51%) received at least 2 week's supply, and 160 (23%) 
received 4 weeks' supply. At first, the monitoring database was 
not structured to indicate the number of women who initiated 
treatment (as expected) at 36 weeks. This was adjusted to 
provide this information for the second period. Of the women 
71% received at least one dose of ZDV during labour. 
Of 252 (44%) records reviewed from the second period, 162 
(64%) received at least one week's supply of ZDV, 143 (57%) 
received at least 2 weeks' supply and 81 (32%) received 4 
weeks' supply. Of these 59% received their first supplies of 
ZDV at 34 weeks, representing successful treatment initiation; 
8% of women received at least one dose during labour, and 
41% self-administered the first dose of ZDV at the onset of 
labour (this practice was only commenced in the second time 
period). 
There was an improvement in the number of women who 
received any form of ZDV treatment across both MOUs from 
85% in the first period to 93% in the second period, the increase 
being greater in MOU2 than in MOU1. There was also 
improvement in the percentage of women who received 2 or 4 
weeks' supply of ZDV in the second period compared with the 
first period. The median duration of ZDV use was 3 weeks. The 
proportion of women who received at least one dose of ZDV in 
TableT. VoJ·untary counselling and testing 
January 1999 - May 2000 June- December 2000 
Indicator MOU1 MOU2 Total MOU1 MOU2 Total 
New antenata l clil1ic bookings 6437 3 560 9 997 2438 1 704 4142 
HIV test ace pted (%) 3 926/6 437 = 61% 3 319/3 560 = 93% 7 229/9 997 = 72% 1 210/2 438 =50% 1 580/1 704 = 93% 2 790/4142 = 67% 
HIV+ (%) 661 /3 926 = 17% 5 24/3 319 = 16% 1 185/7 229 = 16% 250/1 210 = 21% 317/1 580 = 20% 567/2 790 = 20% 
Average turnaround time I-TN 
results in days 11 10 11 <1 <1 <1 
HIV+ women post test 
counselled (%) 90 97 94 94 84 89 
HLV- women post test 
counselled (%) 87 88 87 97 98 98 
Table II. ZDV administ·ration 
January 1999- May 2000 June - December 2000 
Incticator MOV1 MOU2 Total MOUl MOU2 Total 
HIV+ deliveries 415 295 710 87 165 252 
HJV+ who r c ived any form 
ZDV treatment(%) 338/415 = 81% 265/295 = 90% 603/710 = 85% 77/87 = 89% 158/165 = 96% 235/252 = 93% 
No. at least 1 week ZDV 265/415 = 64% 198/295 = 67% 463/710 = 65% 55/87 = 63% 107/165 = 65% 162/252 = 64% 
<:: 2 weeks' antenatal ZDV 
(regard I ss of dose in labour) 204/415 = 49% 157/295 = 53% 361/710 = 51% 44/.87 = 51% 99/165 = 60% 143/252 =57% 
<:: 4 weeks' ant natal ZDV 
(regardless of dose in labour) 90/415 = 22% 70/295 = 24% 160/710 = 23% 30/87 = 35% 51/165 = 31% 81/252 = 32% 
No. at least 1 dose in labour 260/415 = 63% 245/295 = 83% 505/710 = 71% 70/87 = 81 % 152/165 = 92% 222/252 = 88% 
% women self-administered 
300 mg at ns t of labour 53% 29% 41% 
Treatment initiation at 34 weeks' 
ges tation 49% 69% 59% 
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the intrapartum period increased from 71% to 88% over the 
two periods. 
Results from infant follow-up are not shown and will be 
analysed separately, particularly in respect of lessons to be 
learnt about formula feeding, co-trirnoxazole prophylaxis and 
infant testing for HIV. 
DISCUSSION 
The percentage of women who opted for HIV testing at both 
MOUs across both time periods indicates good acceptability for 
VCT in those attending MOU2. This is likely to be the case in 
similar South African settings. Comparison of the two MOUs in 
the second period showed a significantly higher test consent 
rate at MOU2 (93%), where the HIV test is offered after 
individual counselling, compared with 50% at MOU1, where it 
is offered after group counselling. The lower test acceptance 
rates associated with group counselling are consistent with 
reports from a pilot project in Cote d'Ivoire! indicating the 
superiority of individual O'":er group counselling before a 
choice is made to test. Qualitative research in the two MOUs 
reveals that there is 95% acceptance by patients of individual 
counselling procedures (and at MOU1 half drop out before 
they come to individual counselling) (personal communication 
- S Magwaza). It is likely that use of the rapid test also led to 
an improvement in the administration of post-test counselling 
for all women. It is recommended that adequate resources be 
made available for the counselling component of any MTCT 
programme and that consideration be given to the outsourcing 
of the counselling service to GOs dedicated to this function, 
as was the case in this pilot programme. 
The rate for ZDV initiation at the prescribed gestational age 
(34 weeks after protocol changes) is an important indicator for 
measuring the success of the programme. At 59%, the pilot 
programme can be considered successful with some room for 
improvement. This conclusion is limited by the unavailability 
or records in both time periods under study. Although the rate 
of successful treatment initiation is substantially higher than 
similar programmes in Botswana and Zimbabwe,'"·" rates of 
close to 70% have been achieved in Thailand." 
When considering that in developing countries other 
dedicated and long-established public health programmes 
(such as the Expanded Programme for Immunisation and most 
tuberculosis treatment programmes) have taken many years to 
achieve adequate coverage of over 60%, the achievements of 
the MTCT programme are encouraging, particularly given that 
the MTCT programme is not a stand-alone vertical programme 
but is fully integrated into the primary health care system. The 
relatively early average gestational age at booking indicates 
that commencement of ART at 34 or 36 weeks may generally be 
feasible in the urban South African setting. 
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The administration of at least one dose of ZDV in labour was 
high (71 %) in this programme and improved over time. This 
improvement resulted from protocol changes in the second 
time period with the introduction of self-administration of the 
first dose in labour. 
In the light of the complexity of ZDV administration, the use 
of even shorter courses of antiretrovirals must be given serious 
consideration. A two-dose regimen of nevirapine (l\TVP) (one 
dose to the mother at the onset if labour and one dose to the 
infant within 72 hours of birth) has been shown to reduce 
MTCTby47%.• 
Of the women in our programme 88% received an 
intrapartum dose. This has relevance to an NVP regimen. 
However, the low rate of self-administration (41 %) of the first 
dose of ZDV with the onset of labour in this population may be 
cause for concern where NVP is being considered, since this 
(self-administration) is the preferred method of administration 
for NVP. A combination of self-administration and 
administration in the labour ward where the former is 
unsuccessful ought to achieve 'intrapartum only' treatment 
rates comparable to those described in this programme. 
It is notable that various components of health service 
infrastructure are still fragmented by authority and level. A 
novel co-ordination mechanism termed 'vertical support' 
addressed these structural and functional problems. It is likely 
that the overall improvements in the programme following 
protocol changes were due to the management model 
employed. The correct management approach can have an 
overall impact on the success or otherwise of a programme 
such as this pilot programme at little additional cost. 
CONCLUSIO N 
Subject to the limitations imposed by less than optimal record 
availability, this study has shown that an MTCT programme is 
acceptable in a peri-urban South African setting and is sensitive 
to the availability of a dedicated service providing individual 
VCT. 
The data show that a short-course ZDV regimen can be 
implemented in this setting, although it is logistically complex 
to implement. An 'intrapartum only' dose such as is the case 
with NVP is likely to be logistically easier to implement. 
As NVP is yet to be tested in the field, it is recommended 
that the ZDV programme continue, allowing future 
comparisons between these two regimens. Further research on 
compliance is recommended. Further work is also required on 
regimens which lower transmission rates even further. 
The authors thank all the staH of the facilities where the pilot 
progranune was implemented, and Professor G Hussey and the 
Child Health Unit, UCT. 
ORIGINAL ARTICLES 
References 
1. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva: June 2000. 
2. Connor EM, Sperling RS, Gelber R. et al. Reduction of maternal-infant transmission of human 
immunodeficiency virus type 1 with zidovudine treatment. N Eng! J Med 1994; 331: 1173--1180. 
3. Undegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV I AIDS in 
the United States. JAMA 1999; 2B:Z, 531-538. 
4. Centers for Disease Control and Prevention.. Ad.ministratie>11 of zidovudine during late 
pregnany and delivery to prevent perinatal HJV transmission- Thailand 1996-199 . 
MMWR 1998; 47, 151-154. 
5. Moodley D. The SAINT Trial: evirapine versus zidovudine + lamivudine in p revention of 
peripartum HIV transmission, University of Natal, 13th International AIDS Conference, 
Durban, 9 july 21XXl Available at htq>:/www.iac2QOO.o~/abdetail.asp?lD=LbOr2 
6. Guay LA, Musoke P, Aeming T, et al. Intrapartum and neonatal single-dose nevirapine 
compared v-.'ith zidovud.ine for prevention of mother-to-child transmission of HIV-1 in 
Kampala, Uganda' HJV !ET 012 randomised trial. lAncet vol354, Sept 4, 1999; 354, 
7. Saba j , on behalf of PETRA Trial Study Team. Interim analysis of early efficacy of three short 
ZOV / 3TC combination regimens to prevent mother to child transmission of HIV-L The 
PETRA triaL Abstract 57. 6th Conference on Retroviruses and Opportunistic Infections, 
Chicago, january 31- February 41999. 
8. Department of Health. Report of Annual Antenatal Survey 1999. Pretori"' Department of 
National Health.. 1999. 
9. UNICEF/ UNAJI>S/ WHO/ UNFPA. African regional meeting on pilot projects for the 
prevention of mother-to-child transmission of HN. Gaborone, Botswana. March, 21XKJ. 
Available at httR:/\VW'W.unaids/ org / publications / doruments / mtct/ Gaberone meetin~ 
MTCf.doc. Accessed December 2000. 
10. Mazhani L, Phiri L, Keapoletswe K, Bowelo M, Mugabe M, Mouzin E. Implementation of a 
population-based pilot program to reduce mother-to-child HIV transmission, Botswana. 
From: 13th International AIDS Conference, Durban, 9 july 2000. Available at: 
htW:/www.iac2000.org / abdetaiLasp?fD=WeOrC550 
11. Moyo 5, Mhazo M, Mateta P. von Lieven A, Shetty AK, Hill OW, Basset MT Acceptability of 
short-course ZDV prevention regimen by HJV infected pregnant women: should VCT in the 
antenatal setting be modified? From: 13th International AIDS Conference; july 9, 2000; 
Durban, South Africa. Available at: htn>:/ www.iac200Q.org / abdetail.asp?ID=TuPpB1158 
12. Kanshana 5, Thewanda 0 , Teerarutkul A, Umpakamjanarat K, Amomwichet P, Kullerk N, 
Mastro TO, Simonds Rj . Pilot program to implement short-course ZDV to reduce perinatal 
HIV transmission in Northeastern Titailand. From: 13th International AIDS Conference, 
Durban, 9 July 2000. Available at htW' / www.ia<2!lOO.oq: / abdetail.asp?lD=WeOrC553 
Accepted Bfune 2001 . 
--
AIDS IN AFRICA- SURVIVAL 
ACCORDING TO AIDS-DEFINING 
ILLNESS 
Frank A Post, Motasim Badri, Robin Wood, Gary Maartens 
Objective. Evaluation of prognostic significance of the type 
of AIDS-defining illness (ADI) and performance status in a 
cohort of AIDS patients. 
Design, setting, subjects, outcome measures. A retrospective 
analysis of 280 patients with AIDS, as defined by the 
proposed World Health Organisation (WHO) clinical 
staging system, who attended two Cape Town-based IDV 
clinics between 1984 and 1997. Patients were stratified 
according to the type of initial ADL Survival associated 
with each opportunistic event was determined by Kaplan-
Meier analysis. Cox proportional hazard analysis was used 
to determine relative risk for death associated with three 
strata of ADJ. 
Results. Median survival associated with various initial 
ADis varied from less than 3 months (encephalopathy and 
wasting), to over 2 years (extrapulmonary tuberculosis and 
herpes simplex virus infection). This effect of ADI on 
outcome was most striking in patients with relatively 
preserved CD4 counts (CD4 >50/~) . A performance status 
score 4 predicted 50% mortality at 1 month, irrespective of 
co-morbidity. 
Conclusion. The type of ADI is an important determinant of 
survival, particularly in patients with preserved CD4 
counts. The stratification of patients by type of ADI and 
performance status may be useful in the management of 
patients with adv~ced HN infection in resource-limited 
environments. 
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The disease burden caused by HIV infection has been 
overwhelming health care facilities in many African countries. ' 
It has been suggested that African patients with IDV infection 
have an increased rate of progression from asymptomatic HIV 
infection to AIDS compared with patients in the developed 
world, and this difference has been related to limited access to 
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